Glembatumumab Vedotin
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Glembatumumab vedotin (Celldex) is an antibody–drug conjugate that targets cancer cells expressing glycoprotein non-metastatic B. This fully human monoclonal antibody is linked to monomethyl auristatin E (MMAE), a potent, peptide-derived antimitotic drug which targets microtubules and which is too toxic to be used as a monotherapy. Glembatumumab vedotin uses a valine-citrulline enzyme cleavable linker that is stable in the bloodstream. Once the drug is internalized into the cell, MMAE is released and induces apoptosis.
Analyst Outlook
Glembatumumab vedotin (Celldex) is positioned to be the first antibody–drug conjugate approved for triple-negative breast cancer (TNBC). It is currently in a Phase II registration trial where it is being assessed as a first-, second-, or third-line treatment in metastatic TNBC patients overexpressing the transmembrane glycoprotein non-metastatic B (GPNMB). As an antibody–drug conjugate, glembatumumab vedotin could have a better safety profile than the chemotherapeutics currently being used in metastatic TNBC. Glembatumumab vedotin will be restricted to the subpopulation of TNBC patients that overexpress the GPNMB target; however, it is not yet clear how big this patient group will be.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 glembatumumab vedotin : Breast cancer: triple-negative
LIST OF FIGURES
9 Figure 1: Glembatumumab vedotin for triple-negative breast cancer – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of glembatumumab vedotin for
triple-negative breast cancer
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of glembatumumab vedotin for
triple-negative breast cancer
LIST OF TABLES
4 Table 1: Glembatumumab vedotin drug profile
5 Table 2: Glembatumumab vedotin Phase IIb trial in triple-negative breast cancer
7 Table 3: Glembatumumab vedotin Phase IIb data in triple-negative breast cancer
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sofosbuvir/Velpatasvir/GS-9857 
Sign up to the